AtheroGenics Soars 64 Percent On AGI-1067 Phase IIb Results Sep. 29, 2004 By Aaron Lorenzo AtheroGenics Inc. saw its share value skyrocket on positive clinical trial results that revealed its lead drug candidate cut plaque buildup in heart disease patients. (BioWorld Today)Read More
